|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bernier J, Rossier C and Horiot JC: Recent
advances in regional treatment of breast carcinoma. Crit Rev Oncol
Hemato. 99:107–114. 2016. View Article : Google Scholar
|
|
4
|
Partridge AH: Chemotherapy in
premenopausal breast cancer patients. Breast Care (Basel).
10:307–310. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rakha EA: Pitfalls in outcome prediction
of breast cancer. J Clin Pathol. 66:458–464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hirai H, Maru Y, Hagiwara K, Nishida J and
Takaku F: A novel putative tyrosine kinase receptor encoded by the
eph gene. Science. 238:1717–1720. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pasquale EB: Eph-ephrin bidirectional
signaling in physiology and disease. Cell. 133:38–52. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pasquale EB: Eph receptors and ephrins in
cancer: Bidirectional signalling and beyond. Nat Rev Cancer.
10:165–180. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pasquale EB: Eph receptor signalling casts
a wide net on cell behaviour. Nat Rev Mol Cell Biol. 6:462–475.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li S, Ma Y, Xie C, Wu Z, Kang Z, Fang Z,
Su B and Guan M: EphA6 promotes angiogenesis and prostate cancer
metastasis and is associated with human prostate cancer
progression. Oncotarget. 6:22587–22597. 2015.PubMed/NCBI
|
|
11
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Untch M, Gerber B, Harbeck N, Jackisch C,
Marschner N, Möbus V, von Minckwitz G, Loibl S, Beckmann MW,
Blohmer JU, et al: 13th stGallen international breast cancer
conference 2013 primary therapy of early breast cancer evidence,
controversies, consensus opinion of a german team of experts
(zurich 2013). Breast Care (Basel). 8:221–229. 2013.PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
You Y, Li H, Qin X, Ran Y and Wang F:
Down-regulated ECRG4 expression in breast cancer and its
correlation with tumor progression and poor prognosis-A short
report. Cell Oncol (Dordr). 39:89–95. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Parl FF, Schmidt BP, Dupont WD and Wagner
RK: Prognostic significance of estrogen receptor status in breast
cancer in relation to tumor stage, axillary node metastasis, and
histopathologic grading. Cancer. 54:2237–2242. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Howell SJ, Wardley AM and Armstrong AC:
Re: Ki67 index, HER2 status, and prognosis of patients with luminal
B breast cancer. J Natl Cancer Inst. 101:1730–1731. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wolff AC, Hammond ME, Schwartz JN, Hagerty
KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer
A, et al: American society of clinical oncology/college of American
pathologists guideline recommendations for human epidermal growth
factor receptor 2 testing in breast cancer. J Clin Oncol.
25:118–145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hafner C, Schmitz G, Meyer S, Bataille F,
Hau P, Langmann T, Dietmaier W, Landthaler M and Vogt T:
Differential gene expression of Eph receptors and ephrins in benign
human tissues and cancers. Clin Chem. 50:490–499. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rouzier R, Perou CM, Symmans WF, Ibrahim
N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P,
et al: Breast cancer molecular subtypes respond differently to
preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kourea HP, Zolota V and Scopa CD: Targeted
pathways in breast cancer: Molecular and protein markers guiding
therapeutic decisions. Curr Mol Pharmacol. 7:4–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Payne SJ, Bowen RL, Jones JL and Wells CA:
Predictive markers in breast cancer-the present. Histopathology.
52:82–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gajria D and Chandarlapaty S:
HER2-amplified breast cancer: Mechanisms of trastuzumab resistance
and novel targeted therapies. Expert Rev Anticancer Ther.
11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
English DP, Roque DM and Santin AD: HER2
expression beyond breast cancer: Therapeutic implications for
gynecologic malignancies. Mol Diagn Ther. 17:85–99. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pietras RJ, Pegram MD, Finn RS, Maneval DA
and Slamon DJ: Remission of human breast cancer xenografts on
therapy with humanized monoclonal antibody to HER-2 receptor and
DNA-reactive drugs. Oncogene. 17:2235–2249. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arpino G, Wiechmann L, Osborne CK and
Schiff R: Crosstalk between the estrogen receptor and the HER
tyrosine kinase receptor family: Molecular mechanism and clinical
implications for endocrine therapy resistance. Endocr Rev.
29:217–233. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kamat AA, Coffey D, Merritt WM, Nugent E,
Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL and Sood AK:
EphA2 overexpression is associated with lack of hormone receptor
expression and poor outcome in endometrial cancer. Cancer.
115:2684–2692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhuang G, Brantley-Sieders DM, Vaught D,
Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C and Chen
J: Elevation of receptor tyrosine kinase EphA2 mediates resistance
to trastuzumab therapy. Cancer Res. 70:299–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
